Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Ann Hematol · 2018 · PMC6097797 · PMID 29862437

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

However, we observed a borderline significant effect of more complex genetic alterations as shown by a surrogate of two or more mutations found in our eight-gene panel (median PFS 39.1 months (95% CI 26.0–52.2) vs 70.5 (95% CI 53.2–87.3) p = 0·051; HR 3.35 (95% CI 1.00–0.07) Fig. 2 e).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.